Molecular Genetics of Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
NorthShore University HealthSystem
ClinicalTrials.gov Identifier:
NCT00006418
First received: October 25, 2000
Last updated: April 1, 2014
Last verified: November 2005

October 25, 2000
April 1, 2014
September 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00006418 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Molecular Genetics of Schizophrenia
Not Provided

This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes that predispose people to schizophrenia.

Each site will recruit individuals in a large geographic area, and use efficient ascertainment strategies and assessment procedures in order to maximize the number collected. Subjects thought to have schizophrenia will be assessed by personal and family interviews and a review of medical records. Diagnoses will be made by consensus best-estimate procedures. Blood specimens will be obtained from all individuals with schizophrenia or schizoaffective disorder plus their available parents and also the control individuals. A clinical self-assessment will be administered to each control subject. The assessment will include validated self-assessments of lifetime major depression, anxiety disorders, and substance use, and self-reported history of bipolar or psychotic symptoms. Permanent cell lines will be created and DNA extracted at the NIMH-sponsored Center for Genetic Studies. At the end of the four-year project period, biological materials and blinded pedigree and clinical data will be made available to the scientific community for genetic studies of schizophrenia and related disorders. The control sample will, however, be released in a staggered fashion, twice during each fiscal year, to start during the 2nd year of recruitment. The informed consent for controls includes consent for specimens to be used in research on the genetics of any medical disorder. In years 3 and 4, we will undertake association analyses. Power analyses suggest that this study will have excellent power to detect loci associated with genes with relatively small etiologic effects. Data derived from this study will potentially have applications for the treatment and prevention of schizophrenia.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Schizophrenia
Procedure: DNA collection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10800
August 2007
Not Provided

Inclusion Criteria:

  • Individuals thought to have schizophrenia or schizoaffective disorder, be the parent of such an individual, or be in the matched control group of unrelated individuals not thought to have schizophrenia or schizoaffective disorder

Exclusion Criteria:

  • Unable to give informed consent to all aspects of the study
  • Psychotic disorder judged to be secondary to substance use, psychotic disorder that appears to be secondary to a known medical or neurological disorder, or severe mental retardation
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia
 
NCT00006418
R01 MH59571, R01MH059571, R01 MH59571, R01 MH59588, R01 MH60870, R01 MH59565, R01 MH59566, R01 MH60879, R01 MH59586, R01 MH61675, R01 MH59587, DNBBS 7G-GRR
Not Provided
Not Provided
NorthShore University HealthSystem
National Institute of Mental Health (NIMH)
Not Provided
NorthShore University HealthSystem
November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP